Abstract
Background: Hyaluronan (HA), a glycosaminoglycan, is a key extracellular matrix (ECM) component, and has been established to contribute to fibrotic, angiogenic, inflammatory as well as processes supporting cancer development. The changes in HA deposition in different tumors have been widely studied. Indeed, a multitude of reports demonstrate that HA expression is increased in different neoplasmatic tissues including lung, colon, prostate and breast cancer. The aims of this paper are to critically and in depth discuss aspects of HA metabolism in cancer and recent developments of its utilization in cancer therapy.
Methods: Up to date research and online content are reviewed.
Results: The cellular roles of HA are perpetrated through molecular interactions with HA-binding proteins, called hyaladherins, including CD44 receptor as well as receptor for hyaluronan-mediated motility (RHAMM). HA binding can be followed by receptor-mediated endocytosis. Importantly, hyaladherins show an altered expression in tumor tissues. Indeed, post-translational alterations in CD44 structure have been suggested to regulate the equilibrium between the “inactive” low affinity state and the “active” high affinity state of the HA binding capacity. In this concept HA fragments can be utilized as specific targeting ligands for efficient and safe drug delivery in cancer.
Conclusion: HA-drug bioconjugates and nanoparticles have emerged as a promising platform for drug delivery during cancer treatment as demonstrated in various pre-clinical studies. Recent developments from clinical trials indicate that the utilization of specific HA-drug bioconjugates might be approved for the medical practice in the nearest future.
Keywords: Cancer, CD44, drug delivery, hyaluronan.
Current Drug Delivery
Title:Hyaluronan/Hyaladherins - a Promising Axis for Targeted Drug Delivery in Cancer
Volume: 13 Issue: 4
Author(s): Dragana Nikitovic, Katerina Kouvidi, Rafaela-Maria Kavasi, Aikaterini Berdiaki and George N. Tzanakakis
Affiliation:
Keywords: Cancer, CD44, drug delivery, hyaluronan.
Abstract: Background: Hyaluronan (HA), a glycosaminoglycan, is a key extracellular matrix (ECM) component, and has been established to contribute to fibrotic, angiogenic, inflammatory as well as processes supporting cancer development. The changes in HA deposition in different tumors have been widely studied. Indeed, a multitude of reports demonstrate that HA expression is increased in different neoplasmatic tissues including lung, colon, prostate and breast cancer. The aims of this paper are to critically and in depth discuss aspects of HA metabolism in cancer and recent developments of its utilization in cancer therapy.
Methods: Up to date research and online content are reviewed.
Results: The cellular roles of HA are perpetrated through molecular interactions with HA-binding proteins, called hyaladherins, including CD44 receptor as well as receptor for hyaluronan-mediated motility (RHAMM). HA binding can be followed by receptor-mediated endocytosis. Importantly, hyaladherins show an altered expression in tumor tissues. Indeed, post-translational alterations in CD44 structure have been suggested to regulate the equilibrium between the “inactive” low affinity state and the “active” high affinity state of the HA binding capacity. In this concept HA fragments can be utilized as specific targeting ligands for efficient and safe drug delivery in cancer.
Conclusion: HA-drug bioconjugates and nanoparticles have emerged as a promising platform for drug delivery during cancer treatment as demonstrated in various pre-clinical studies. Recent developments from clinical trials indicate that the utilization of specific HA-drug bioconjugates might be approved for the medical practice in the nearest future.
Export Options
About this article
Cite this article as:
Nikitovic Dragana, Kouvidi Katerina, Kavasi Rafaela-Maria, Berdiaki Aikaterini and N. Tzanakakis George, Hyaluronan/Hyaladherins - a Promising Axis for Targeted Drug Delivery in Cancer, Current Drug Delivery 2016; 13 (4) . https://dx.doi.org/10.2174/1567201813666151109103013
DOI https://dx.doi.org/10.2174/1567201813666151109103013 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advancements in Robotic and AI-Based Drug Discovery and Delivery for Neurological Disorders
Neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and brain tumors, pose significant challenges in drug delivery due to the blood-brain barrier's intricate structure and the complexity of neuronal networks. Traditional drug delivery methods often fall short in reaching therapeutic concentrations within the central nervous system, limiting treatment efficacy and ...read more
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access to both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recents Patents for Isolating, Delivering and Tracking Adult Stem Cells in Regenerative Medicine
Recent Patents on Drug Delivery & Formulation New Medical Strategies for Midgut Carcinoids
Anti-Cancer Agents in Medicinal Chemistry Novel Perspectives for the Diagnosis and Treatment of Gynecological Cancers using Dysregulation of PIWI Protein and PiRNAs as Biomarkers
Current Medicinal Chemistry Downregulation of miR-140 is Correlated with Poor Prognosis and Progression of Thyroid Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Organosulfur Compounds in Cancer Chemoprevention
Mini-Reviews in Medicinal Chemistry Isoprenylation of Intracellular Proteins as a New Target for the Therapy of Human Neoplasms: Preclinical and Clinical Implications
Current Drug Targets Identification and Usage of Fluorescent Probes as Nanoparticle Contrast Agents in Detecting Cancer
Current Pharmaceutical Design Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry Role of PPAR in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery The Membrane-targeted Alkylphosphocholine Erufosine Interferes with Survival Signals from the Extracellular Matrix
Anti-Cancer Agents in Medicinal Chemistry Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Soy Isoflavones and their Effects on Xenobiotic Metabolism
Current Drug Metabolism Head and Neck Cancer Treatments through Chemotherapy to Magnetic Systems: Perspectives and Challenges
Current Radiopharmaceuticals Perspectives in Breast and Ovarian Cancer Chemotherapy by Nanomedicine Approach: Nanoformulations in Clinical Research
Current Medicinal Chemistry Molecular Imaging of Therapeutic Potential of Reporter Probes
Current Drug Targets Dinuclear Berenil-Platinum (II) Complexes as Modulators of Apoptosis in Human MCF-7 and MDA-MB231 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Cerebral Angiogenesis and Expression of Angiogenic Factors in Aging Rats after Exercise
Current Neurovascular Research Congenital Choledochal Malformation – Current Concepts and Classification
Current Pediatric Reviews The Diversity of Epithelial Secreted Mucins
Current Organic Chemistry Targeted Gene Therapy for Ovarian Cancer
Current Gene Therapy